Groowe Groowe / Newsroom / ESLA
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

ESLA News

Estrella Immunopharma, Inc. Common Stock

Form 8-K

sec.gov
ESLAW ESLA

Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase

businesswire.com
ESLA

Form 8-K

sec.gov
ESLAW ESLA

Form 8-K

sec.gov
ESLA ESLAW

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

businesswire.com
ESLA

Form 8-K

sec.gov
ESLAW ESLA

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT ® & CIBMTR ®

businesswire.com
ESLAW ESLA

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

businesswire.com
ESLA

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

businesswire.com
ESLA

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

businesswire.com
ESLA